Years of innovative and dedicated research have paid off with the discovery of numerous factors contributing to Alzheimer’s disease (AD) pathology. With a disease as complex as this one, it’s very helpful to find multiple points where it may be possible to slow or halt its progress.
These discoveries have produced a bounty of “druggable targets”. Unfortunately, only a handful of potential “disease-modifying treatments” ever make it to the point of being tested in clinical trials, where a few are being tested today.
Support is needed for the type of high-risk, high-reward early research where discoveries in basic science may lead to the development of molecules and compounds aimed at reducing toxic protein buildup in AD, improving clearance of toxic particles, and delivering treatments to brain areas. The contributions gained from these exploratory projects at early stages are essential to get the next generation of drugs and therapies to patients.
Explore More of Our 360° Research Approach
- Tangling with Tau
- Battling Amyloid Beta
- Blood and the Brain in Dementia
- Immunity and Inflammation
- Biology of APO E and Lipids
- Cell Death
Genes are the “master blueprint” that instructs our cells to make unique proteins which in turn build, operate, and repair human tissue. Humans have an estimated 24,000 genes along our 23 matched pairs of chromosomes (46 in all), and “genomics” refers to the field that studies all of them at once.
A biological marker (biomarker) is a measurable substance in an organism whose presence is indicative of some phenomenon such as disease or infection. Biomarkers can help doctors and scientists diagnose diseases and health conditions, find health risks in a person, monitor responses to treatment, and see how a person's disease or health condition changes over time.
Tangling with Tau
Tau is a small protein with a short name but a large reputation because of its association with multiple brain diseases, including Alzheimer’s disease (AD). The tau protein is predominantly found in brain cells (neurons).
Battling Amyloid Beta
There are many versions of amyloid protein in the human body, and most serve a useful role. One of the hallmarks of Alzheimer’s disease (AD) is the accumulation of amyloid plaques (abnormally configured proteins) between nerve cells (neurons) in the brain.
Blood and the Brain in Dementia
Scientists are interested in developing a screening tool for Alzheimer’s disease (AD) in blood. A simple blood draw is much less invasive than a spinal tap and may prove more cost effective. Developing blood biomarkers that accurately depict brain changes has proven challenging, as levels of AD hallmark proteins in the blood are low, but there are some very recent promising results observing tau and the ratio of Aβ42 and Aβ40.
Immunity and Inflammation
One theory about Alzheimer’s disease (AD) is that it may be triggered, in part, by a breakdown in the brain’s immune system.
Biology of APO E and Lipids
Alzheimer's disease (AD). Its primary function is to regulate a class of proteins involved in the metabolism of fats (lipids) in the body. However, APOE has several common variants (or "alleles") whose effects vary.
The human brain has an estimated 100 billion neurons. Extending from each of them is a long fiber, known as an “axon,” which can run several feet. Each axon forms a connection, known as a “synapse” with another neuron, creating a circuit over which brain signals travel. In Alzheimer’s disease (AD), individual neurons die and do not regenerate; while others have brains that are more are resilient and respond to meet changing demands.